|
|
Article: High levels of adamantane resistance among influenza a (H3N2) viruses and interim guidelines for use of antiviral agents--United States, 2005-06 influenza season.
- Article from:
- MMWR. Morbidity and Mortality Weekly Report
- Article date:
- January 20, 2006
- Author:
CopyrightCOPYRIGHT 2006 U.S. Government Printing Office. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
On January 17, this report was posted as an MMWR Dispatch on the MMWR website (http://www.cdc.gov/mmwr).
An estimated 200,000 persons are hospitalized each year and 36,000 persons die from complications of influenza in the United States (1,2). The cornerstone of influenza prevention is annual vaccination. However, antiviral drugs are an important adjunct to vaccination for influenza prevention and control. Two classes of antiviral medications are available currently: adamantanes or M2 ion channel inhibitors (i.e., amantadine and rimantadine) and neuraminidase inhibitors (i.e., oseltamivir and zanamivir). The adamantanes are active against only influenza A viruses ...